Healthcare - Biotechnology - NASDAQ - US
$ 3.22
-2.72 %
$ 272 M
Market Cap
-1.56
P/E
CASH FLOW STATEMENT
-85.4 M
OPERATING CASH FLOW
40.3 M
INVESTING CASH FLOW
257 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Atea Pharmaceuticals, Inc.
| Net Income | -136 M |
| Depreciation & Amortization | 416 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 49.4 M |
| Change in Working Capital | 16.2 M |
| Others | 47.6 M |
| Free Cash Flow | -85.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (136.0) | (115.9) | 121.2 | (10.9) | (14.0) | (9.1) |
| Depreciation & Amortization | 0.4 | 0.3 | 29 K | 19 K | 17 K | 17 K |
| Deferred Income Tax | (48.6) | 0 | (29.4) | (13.8) | (0.5) | 0 |
| Stock Based Compensation | 49.4 | 46.7 | 39.6 | 7.5 | 0.6 | 0.4 |
| Other Operating Activities | 33.1 | (5.5) | 29.4 | 13.8 | 0.5 | 0.5 |
| Change in Working Capital | 16.2 | (46.6) | (247.8) | 300.2 | 0.6 | 0.7 |
| Cash From Operations | (85.4) | (121.0) | (87.0) | 296.7 | (12.8) | (7.9) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | (1.9) | 4 K | 26 K | 2 K | 12 K |
| Other Items | 40.3 | (453.5) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 40.3 | (455.4) | 4 K | 26 K | 2 K | 12 K |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | 0.1 | 0 | 214.1 | 0 | 54.8 |
| Cash From Financing Activities | 0.3 | 0.4 | 1.5 | 531.7 | 15 K | 27.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (44.8) | (576.0) | (85.5) | 828.5 | (12.8) | 19.6 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (85.4) | (122.9) | (87.0) | 296.7 | (12.8) | (7.9) |